Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PKLR | P30613 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290577 | 0.86 | HTR6 (0.63) | HTR6PKMSMN1; SMN2LMNAPKLR | |
| SCHEMBL9178059 | 0.80 | ALDH1A1 (0.64) | PKMSMN1; SMN2LMNAATMBRD4 | |
| SCHEMBL2906268 | 0.78 | PKM (0.55) | HTR6PKMSMN1; SMN2LMNAPKLR | |
| SCHEMBL749515 | 0.78 | HTR6 (0.73) | HTR6PKMSMN1; SMN2LMNAPKLR | |
| Hydrochloric Acid SCHEMBL732461 | 0.77 | HTR6 (0.74) | HTR6PKMSMN1; SMN2LMNAPKLR | |
| Hydrochloric Acid SCHEMBL732462 | 0.77 | HTR6 (0.74) | HTR6PKMSMN1; SMN2LMNAPKLR | |
| SCHEMBL30326699 | 0.77 | DRD2 (0.58) | HTR6SMN1; SMN2LMNABRD4ALDH1A1 | |
| SCHEMBL28383011 | 0.77 | DRD2 (0.58) | HTR6SMN1; SMN2LMNABRD4ALDH1A1 | |
| SCHEMBL2581047 | 0.77 | PKM (1.00) | PKMPKLRALDH1A1 | |
| SCHEMBL28379967 | 0.77 | HSD17B2 (0.56) | PKMSMN1; SMN2LMNAPKLRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202222-A2 | Indene derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-06-30 | — | — | EP | claimed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | claimed |
| CN-101356149-A | Indene derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2009-01-28 | — | — | CN | claimed |
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| US-8138210-B2 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-03-20 | — | — | US | disclosed |
| EP-2202222-A2 | Indene derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| US-20100069378-A1 | SUBSTITUTED INDANYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-18 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| CN-101356149-A | Indene derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2009-01-28 | — | — | CN | disclosed |
| EP-1884515-A1 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-02-06 | — | — | EP | disclosed |
| US-20080027073-A1 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-01-31 | — | — | US | disclosed |
| WO-2007054257-A2 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027073-A1 | Substituted indanyl sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, GPR6 | HTR6 1/4885PKM 2059/4885SMN1; SMN2 3328/4885 |
| US-20100069378-A1 | SUBSTITUTED INDANYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, GPR6 | HTR6 1/4885PKM 1949/4885SMN1; SMN2 3411/4885 |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR1A | HTR6 1/4885PKM 1938/4885SMN1; SMN2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.